Clinical Trial Update: A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Gadoquatrane to an existing MRI contrast agent completed, evaluating its performance and safety in patients with known or suspected br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Disorders
• Central Nervous System Disorders
• Spinal Cord Disorders

Drugs mentioned

• Gadoquatrane (gadoquatrane)

Snippet

Sponsor: Bayer | Conditions: Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology | Phase 3 | Status: COMPLETED